



## **TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference**

April 8, 2026

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25<sup>th</sup> Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.

A webcast of the fireside chat will be available on the "[Events and Presentations](#)" section of the Company's website at [ir.tscan.com](http://ir.tscan.com). An archived replay of the webcast will be available on the Company's website for 90 days following the event.

### **About TScan Therapeutics, Inc.**

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is in early stages of developing methods for *in vivo* engineering to treat solid tumors. The Company is also applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

### **Investor and Media Contact**

Caileigh Dougherty  
857-399-9890  
[ir@tscan.com](mailto:ir@tscan.com)